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Associations of maternal lipoprotein particle
distribution in mid‑pregnancy with birth
outcomes: a pilot study
Todd C. Rideout1*, Xiaozhong Wen2, Divya Choudhary1, Marissa Catanzaro1, Richard W. Browne3,
Vanessa M. Barnabei4 and Kai Ling Kong5,6,7

Abstract
Background: An excessive rise in maternal lipids during pregnancy may have detrimental impacts on maternal and
fetal health leading to adverse pregnancy outcomes. However, knowledge gaps exist with respect to the association
between lipid biomarkers and birth outcomes.
Methods: We conducted a secondary data analysis of healthy pregnant women (N = 25) with mid-pregnancy fasting
serum samples collected at 22–28 weeks of gestation and birth outcome data. Serum was analyzed for conventional
lipid profile (total-C, HDL-C, LDL-C, and triglycerides) and lipoprotein subclass distribution, including particle number
(nM) and size (nm), for very low-density lipoprotein (VLDL)/chylomicron (CM), low density lipoprotein (LDL), and highdensity lipoprotein (HDL), by nuclear magnetic resonance spectroscopy.
Associations between maternal lipids and birth outcomes, including birth weight (g) and gestational age (weeks),
were assessed using multivariable linear regression, adjusted for pre-pregnancy BMI.
Results: Although conventional lipids were not associated (p > 0.05) with birth outcomes, every 1-unit increment in
large VLDL/CM particles (nM) and VLDL/CM size (nm) was associated with an increase in birth weight (confounderadjusted β-coefficient, 45.80 g [5.30, 86.20, p = 0.003] and 24.90 g [8.80, 40.90, p = 0.002], respectively). Among the
HDL subclass parameters, a 1-unit (nM) increase in the concentration of total HDL-particles was associated with a
reduced birth weight (confounder adjusted β-coefficient, -19.40 g [95% confidence interval, -36.70, -2.20]; p = 0.03)
after adjustment for maternal pre-pregnancy BMI.
Conclusion: The preliminary results of this pilot study suggest that total particle concentrations of VLDL/CM and
HDL in mid-pregnancy have divergent associations with birth weight, potentially reflecting the specific roles of these
lipoprotein particles with respect to placental function and fetal growth.
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Background
To support placental development and optimal nutrient transfer to the growing fetus, a physiological rise in
maternal blood lipids is observed during pregnancy,
exemplified by transient but substantial increases
in triglycerides (TG, ~ 200–400%), total-cholesterol
(TC, ~ 25–50%), low-density lipoprotein cholesterol
(LDL-C, ~ 70%), and high-density lipoprotein cholesterol
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(HDL-C, ~ 40%) [1, 2]. However, an excessive, non-physiological increase in maternal lipids during pregnancy
has been reported to have detrimental effects on both
maternal and fetal health. Excessive maternal hypertriglyceridemia during pregnancy, due to exacerbating
secondary factors such as diabetes and obesity, has been
associated with acute pancreatitis [3], preeclampsia [4],
and adverse birth outcomes including preterm delivery and macrosomia [5]. Similarly, an excessive rise in
maternal cholesterol during pregnancy, termed maternal
hypercholesterolemia (MHC), has been associated with
a range of pregnancy conditions including glucose intolerance [6], gestational diabetes [7], polycystic ovary syndrome [8], and preeclampsia [9].
As blood lipid assessment is not a routine component of obstetrical care [10], there are still knowledge
gaps with respect to what constitutes a ‘normal’ blood
lipid profile during pregnancy and the most appropriate lipid screening marker for maternal dyslipidemia.
With numerous candidate biomarkers including standard
lipid endpoints (i.e., TG, TC, LDL-C, HDL-C), apolipoproteins, as well as more advanced lipoprotein subclass
distribution (i.e., particle number and size), there is little
understanding of the biomarker(s) that is most reflective of an adverse maternal environment. Given these
knowledge gaps, we conducted a pilot study to explore
potential associations between pregnancy lipids, including conventional lipid panel and lipoprotein subclass distribution, and birth outcomes from a previous pregnancy
cohort study.
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Methods
Participants

This study was a secondary analyses of serum samples
and birth outcome data collected as part of a previous pregnancy pilot cohort to examine the reinforcing
value of high-energy-dense foods during pregnancy
(not published). All procedures were approved by the
Institutional Review Board at the University at Buffalo (STUDY00001381). The cohort consisted of 25,
18–35-year-old pregnant women with singleton gestations, recruited within the greater Buffalo, New York area
between 2018–2019 through flyer distribution, social
media posts, and local urban obstetrics clinics (Table 1).
Women were excluded if they had a history of major
chronic diseases (e.g., heart disease, diabetes) or were
currently taking medications that affected appetite or
insulin sensitivity.
Data collection

Upon study enrollment, prospective women completed
an interviewer-administered questionnaire to obtain
information regarding general socio-demographics and
reproductive and medical history. Maternal pre-pregnancy height and weight were collected by self-report at
the initial visit and body mass index (BMI) was calculated
as weight in kilograms divided by the square of height
in meters. At mid-pregnancy between gestation weeks
22–28, a fasting blood sample was collected by a blood
draw technician. A birth outcome questionnaire administered at a home visit within 7 days of birth was used to

Table 1 Characteristics of mothers and infants from the pilot cohort
Variable
Maternal Characteristics (N = 25)
Age (yrs)

Mean (SD)

n (%)

30.7 (3.96)

Range

21.6 – 37.8

Race
Caucasian

23 (92)

African American

1 (4.0)

Asian
Education level (yrs)

1 (4)
16.1 (2.1)

College graduate

23 (92)

Pre-pregnancy BMI (kg/m2)

19.2–41.6

Normal

10 (40)

Overweight

7 (28)

Obese

8 (32)

Infant Characteristics
Male sex
Birth weight (g)

16 (64)
3543 (333)

Large for gestational age a
Gestational age at delivery (weeks)
a

10 (40)
39.28 (0.89)

defined as birthweight greater than the 90th percentile for gestational age
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collect information on infant variables (i.e., date of delivery, sex, birth weight, and gestational age as assessed by
ultrasound examination) and pregnancy complications
(i.e., gestational diabetes, pre-eclampsia, and pre-term
birth).
Serum lipid analyses

Following a blood clotting period of 30 min at room
temperature, maternal serum samples were separated
by centrifugation at 3000 × g for 20 min and stored at
-80 °C. TC, HDL-C, direct LDL-C, and TG were measured by direct automated enzymatic assay using diagnostic reagent kits, calibrators, and quality controls. Direct
assessment of lipoprotein subclass distribution, including
particle number (nM) and size (nm), for very low density
lipoprotein (VLDL)/chylomicron (CM), low density lipoprotein (LDL), and high density lipoprotein (HDL), was
conducted by nuclear magnetic resonance spectroscopy
(NMR) using automated signal acquisition followed by
computational analysis and proprietary signal processing algorithms (LabCorp Inc, Raleigh, NC) [11]. The
diameter size ranges for each lipoprotein subclass were:
VLDL/CM (large, > 60 nm; intermediate, 42–60 nm;
small 29–41 nm); LDL (large, 23–29 nm; intermediate, 20.5–23 nm; small 18–20.5 nm) and; HDL (large,
9.4–14 nm; intermediate, 8.2–9.4 nm; small 7.3–8.2 nm).
ApoB was measured by immunologic analyses (Liposcience, Raleigh, NC) and non-HDL cholesterol was calculated by subtracting HDL-C from TC.
Statistical analyses

Associations between maternal second trimester lipids
and continuous birth outcomes including birth weight (g)
and gestational age (weeks) were assessed using multivariable linear regression. We considered maternal age and
pre-pregnancy BMI as potential confounders that could
affect both maternal pregnancy lipid status and birth outcomes. Significant confounders (p < 0.05), as estimated by
linear regression, were included in the adjusted model.
Two models were used in the analysis: (i) Model 1 was
the crude model with second trimester lipid exposure
only; and (ii) Model 2 adjusted for maternal pre-pregnancy BMI (the only significant confounder). All analyses were conducted using SAS version 9.4 (SAS Institute,
Inc., Cary, NC). Statistical significance was set at a twosided alpha level of p < 0.05.

Results
Mothers included in this study were mainly Caucasian
(92%), highly educated (92% college educated), and overweight or obese according to pre-pregnancy BMI (60%)
(Table 1). With the exception of a breech birth (n = 1),
no pregnancy complications were reported and mean
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infant birth weight and gestational age at delivery was
3543 ± 333 g and 39.28 ± 0.89 weeks, respectively.
Standard lipid profile measures, including cholesterol
(TC, LDL-C, HDL-C, and non-HDL-cholesterol), TG,
and apoB were unrelated (p > 0.05) to birth weight or
gestational age (Table 2). After adjustment for maternal pre-pregnancy BMI, every 1-unit increment in large
VLDL/CM particles (nM) and VLDL/CM size (nm) was
associated with an increase in birth weight (confounderadjusted β-coefficient, 45.80 g [95% confidence interval,
5.30, 86.20, p = 0.003] and 24.90 g [8.80, 40.90, p = 0.002],
respectively) (Table 3). Although LDL subclass distribution was not associated with birth outcomes (Table 4),
among the HDL subclass parameters, every 1-unit (nM)
increment in the concentration of total HDL-particles
was associated with a reduced birth weight (confounderadjusted β-coefficient, -19.40 g [95% confidence interval,
-36.70, -2.20]; p = 0.03) after adjustment for maternal
pre-pregnancy BMI (Table 5). Lipoprotein subclass
parameters for VLDL/CM, LDL, or HDL were not associated (p < 0.05) with gestational age.

Discussion
The results of this pilot study suggest that specific maternal lipoprotein subclass parameters in pregnancy may be
predictive biomarkers of infant birth weight. Although
birth weight was not associated with conventional lipid
assessments, unit increases in the concentration of midpregnancy VLDL/CM lipoproteins (total particle concentration and size) were associated with increased infant
birth weight while total HDL particles were associated
with reduced birth weight. This divergent lipoproteinspecific association may reflect the unique functional
roles of VLDL and HDL lipoproteins in maternal fuel
metabolism and placental/fetal development during
pregnancy.
Pregnancy is associated with adaptive changes in the
metabolism of the large triglyceride-rich lipoproteins
including chylomicrons of intestinal origin and VLDL
which transport de novo synthesized lipids from the liver.
By late pregnancy, serum TG increases by 200–400%
due to a decrease in insulin sensitivity. The subsequent
influx in adipose-derived fatty acids to the liver results
in an estrogen-induced increase in VLDL production
and secretion [2]. Late pregnancy is further associated
with reduced clearance of TG-rich lipoproteins due to a
decrease in lipoprotein and hepatic lipase [12]. Maternal–fetal transfer of fatty acids is mediated by lipoprotein receptor binding and extracellular TG hydrolysis
by lipase expression on the placental syncytiotrophoblast layer [13]. The association we observed between
mid-pregnancy VLDL/CM (total particle concentration
and size) and birth weight is consistent with the role of
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Table 2 Association between maternal second trimester lipid profile and pregnancy outcomes
Birth weight (g) β (95% CI)*
N = 25

Lipid exposure

P-value

Gestational age (weeks) β (95% CI)*
N = 25

P-value

Total-C (mg/dL)
Model 1

-0.80 (-4.20,2.60)

0.65

0.003 (-0.01,0.01)

0.57

Model 2

-0.40 (-3.80,3.00)

0.82

0.001 (-0.01,0.01)

0.81

LDL-C (mg/dL)
Model 1

0.40 (-4.00,4.80)

0.86

0.002 (-0.01,0.01)

0.74

Model 2

0.70 (-3.60,5.00)

0.75

0.001 (-0.01,0.01)

0.88

HDL-C (mg/dL)
Model 1

-4.90 (-11.10,1.20)

0.12

0.003 (-0.01,0.02)

0.73

Model 2

-4.20 (-10.60,2.30)

0.21

-0.002 (-0.02,0.02)

0.85

nonHDL-C (mg/dL)
Model 1

0.80 (-3.20,4.80)

0.69

0.003 (-0.01,0.01)

0.65

Model 2

0.90 (-3.00,4.70)

0.66

0.002 (-0.01,0.01)

0.69

Triglycerides (mg/dL)
Model 1

1.40 (-1.40,4.10)

0.32

0.003 (0.00,0.01)

0.45

Model 2

1.10 (-1.70,3.80)

0.45

0.005 (0.00,0.01)

0.21

Model 1

1.30 (-4.90,7.50)

0.67

0.002 (-0.01,0.02)

0.78

Model 2

1.50 (-4.60,7.50)

0.63

0.002 (-0.01,0.02)

0.83

ApoB (mg/dL)

*

Values are beta coefficients (95% CI) derived from linear regression models, representing the change in birth weight (g) or gestational age (weeks) with one unit
increment in each lipid exposure; Model 1: crude model; Model 2: adjusted for maternal pre-pregnancy BMI

Table 3 Association between maternal second trimester VLDL/Chylomicron (CM) lipoprotein profile and pregnancy outcomes
Lipid exposure

Birth weight (g) β (95% CI)* N = 25

P-value

Gestational age (weeks) β (95% CI)*
N = 25

P-value

Total VLDL/CM particles (nM)
Model 1

-1.20 (-6.50,4.00)

0.64

-0.002 (-0.02,0.01)

0.80

Model 2

-1.60 (-6.70,3.50)

0.55

-0.001 (-0.01,0.01)

0.93

Small VLDL/CM particles (nM)
Model 1

-3.40 (-11.20,4.40)

0.40

-0.014 (-0.03,0.01)

0.17

Model 2

-4.30 (-12.00,3.30)

0.27

-0.012 (-0.03,0.01)

0.25

Medium VLDL/CM particles (nM)
Model 1

-2.10 (-12.50,8.40)

0.70

0.017 (-0.01,0.04)

0.24

Model 2

-1.40 (-11.70,9.00)

0.80

0.014 (-0.01,0.04)

0.30

Large VLDL/CM particles (nM)
Model 1

48.30 (10.70,85.80)

0.01

0.026 (-0.09,0.14)

0.65

Model 2

45.80 (5.30,86.20)

0.03

0.070 (-0.04,0.18)

0.22

VLDL/CM size (nm)
Model 1

25.90 (9.80,42.00)

0.002

0.023 (-0.03,0.07)

0.30

Model 2

24.90 (8.80,40.90)

0.002

0.029 (-0.02,0.08)

0.23

*

Values are beta coefficients (95% CI) derived from linear regression models, representing the change in birth weight (g) or gestational age (weeks) with one
increment change in each lipid exposure; Model 1: crude model; Model 2: adjusted for maternal pre-pregnancy BMI

TG-rich lipoproteins in transporting fatty acid fuel for
placental uptake. However, maternal TG concentration
was not associated with birth weight, even though previous studies have reported a positive association [14–16].
Only limited work has examined potential associations

between VLDL subclass distribution and fetal growth
parameters. VLDL particle concentration in mid-pregnancy has been reported to be increased in women with
gestational diabetes [17], a pregnancy condition often
linked to large for gestation age birth [18]. However,
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Table 4 Association between maternal second trimester LDL lipoprotein profile and pregnancy outcomes
Birth weight (g) β (95% CI)* N = 25

P-value

Gestational age (weeks) β (95%
CI)* N = 25

P-value

Model 1

0.20 (-0.30,0.70)

0.42

0.00 (0.00,0.00)

0.70

Model 2

0.20 (-0.20,0.70)

0.37

0.00 (0.00,0.00)

0.76

Model 1

0.00 (-0.50,0.50)

0.93

-0.001 (0.00,0.00)

0.11

Model 2

-0.10 (-0.60,0.40)

0.64

-0.001 (0.00,0.00)

0.24

Lipid exposure
Total LDL particles (nM)

Small LDL particles (nM)

Intermediate LDL particles (nM)
Model 1

0.30 (-0.50,1.10)

0.47

0.002 (0.00,0.00)

0.09

Model 2

0.30 (-0.50,1.10)

0.44

0.002 (0.00,0.00)

0.08

Model 1

0.10 (-0.30,0.50)

0.66

0.001 (0.00,0.00)

0.37

Model 2

0.20 (-0.20,0.70)

0.38

0.001 (0.00,0.00)

0.67

Model 1

-141.50 (-386.80,103.80)

0.26

0.466 (-0.18,1.11)

0.16

Model 2

-111.80 (-362.10,138.60)

0.38

0.348 (-0.30,1.00)

0.20

Large LDL particles (nM)

LDL size (nm)

*

Values are beta coefficients (95% CI) derived from linear regression models, representing the change in birth weight (g) or gestational age (weeks) with one unit
increment in each lipid exposure; Model 1: crude model; Model 2: adjusted for maternal pre-pregnancy BMI

Table 5 Association between maternal second trimester HDL lipoprotein profile and pregnancy outcomes
Lipid exposure

Birth weight (g) β (95% CI)* N = 25

P-value

Gestational age (weeks) β (95% CI)*
N = 25

P-value

Total HDL particles (μM)
Model 1

-20.90 (-37.80,-3.90)

0.02

-0.009 (-0.06,0.05)

0.75

Model 2

-19.40 (-36.70,-2.20)

0.03

-0.018 (-0.07,0.03)

0.51

Small HDL particles (μM)
Model 1
Model 2

2.60 (-24.20,29.50)

0.85

-0.033 (-0.10,0.04)

0.36

1.00 (-25.30,27.40)

0.94

-0.027 (-0.09,0.04)

0.43

Medium HDL particles (μM)
Model 1

-14.30 (-34.50,6.00)

0.17

0.003 (-0.06,0.05)

0.93

Model 2

-12.80 (-32.90,7.30)

0.21

-0.001 (-0.06,0.04)

0.73

Large HDL particles (μM)
Model 1

-19.60 (-56.80,17.50)

0.30

0.044 (-0.06,0.14)

0.39

Model 2

-15.50 (-53.10,22.00)

0.42

0.027 (-0.07,0.13)

0.59

HDL size (nm)
Model 1

55.80 (-361.80,473.30)

0.79

0.923 (-0.13,1.98)

0.09

Model 2

107.60 (-306.40,521.60)

0.61

0.773 (-0.27,1.81)

0.14

*

Values are beta coefficients (95% CI) derived from linear regression models, representing the change in birth weight (g) or gestational age (weeks) with one unit
increment in each lipid exposure; Model 1: crude model; Model 2: adjusted for maternal pre-pregnancy BMI

the finding of Roland et al. [19] suggest that low placental CETP activity in late gestation was associated with
reduced TG exchange, large TG-rich VLDL/chylomicron
particles, and reduced fetal growth, potentially reflecting
altered placental lipid uptake.
Interestingly, neither maternal TG nor VLDL subclass parameters in mid-pregnancy were associated with

gestation age. Previous work has reported that elevated
maternal TG concentration in pre-pregnancy [20] and
early pregnancy (< 15 weeks) [21] were associated with
an increased risk of pre-term birth, a finding that is
somewhat supported by a previous systematic review,
although data between studies were highly heterogeneous [22]. Further, Catov et al. (2017) reported that low
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total VLDL particle concentration (mainly due to fewer
small VLDL particles) in the first trimester was associated with pre-term birth [23]. This data might suggest
that early pregnancy TG/VLDL status might be more
predictive of pre-term birth than mid-pregnancy concentrations, however, future work should examine how the
trajectory of changes in lipid and lipoprotein concentrations across pregnancy influence gestation age.
Although total and LDL-C concentrations increase
substantially throughout gestation, the rise in maternal HDL-C is relatively minor and has been reported to
peak in the 2nd trimester [24, 25]. There is a dearth of
research pertaining to HDL subclass distribution during
pregnancy, however, a shift in HDL subclass particles is
thought to occur throughout the gestation period. Previous studies have reported an increase in larger, TGrich HDL particles (HDL2a) and a reduction in smaller
(HDL3a and b) species throughout gestation [26–28].
Alternatively, Zeljkovic et al. (2013) [24] reported an
increase in small HDL particles (HDL3b and 3c) and a
concurrent reduction in small HDL2a particles as pregnancy progressed. These conflicting reports may reflect
the complex array of metabolic factors regulating HDL
remodeling including plasma factors, adiposity status,
and yet-to-be identified pregnancy-induced factors [29,
30].
Outside of pregnancy, HDL is most typically recognized as a cardioprotective mediator of reverse cholesterol transport. However, during pregnancy, HDL
has a range of other diverse functions that may specifically influence placental metabolism and fetal growth,
as recently reviewed by Woollett et al. [31]. First, as a
lipid carrier, HDL serves to directly support fetal growth
by delivering lipid fuels through placental lipoprotein
receptors and perhaps indirectly by sparing of maternal glucose for placental uptake [32]. Second, a diverse
range of bioactive proteins are associated with specific
HDL subclasses including apolipoprotiens, enzymes, and
complement proteins, which confer antioxidative, antiinflammatory, and immune functions to HDL [33]. The
recently observed pregnancy-specific shift in the HDL
proteome suggests critical, but as yet unknown, role(s)
for specific HDL subclasses in fetal growth and development [28]. For instance, an increase in the proportion of
larger HDL particles in pregnancy has previously been
associated with preterm birth [23] and reduced birth
length and head circumference [24]. Interestingly, in our
cohort, we observed a negative association between total
HDL particles and birth weight, but a similar association
with HDL-C was not observed, highlighting a potentially
important function of HDL in pregnancy beyond cholesterol transport. In support of this finding, a recent study
reported that women giving birth to small-for-gestational
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age (SGA) infants had higher total HDL particles at
36–38 weeks of pregnancy compared with women giving
birth to appropriate-for-gestational age (AGA) infants
[19]. Similarly, Kramer et al. previously reported an
elevated risk of SGA infants across quartiles of maternal total (adjusted odds ratio, 2.8; 95% CI, 1.7–4.5) and
small (1.6; 1.04–2.5) HDL particle concentration between
24–26 weeks of gestation. As some studies have reported
a protective effect of HDL-C against low birth weight
[34], the authors suggested that this counterintuitive
finding was not likely causative but rather a consequence
of placental dysfunction. Likewise, while our findings
may reflect a dysregulation in HDL particle turnover, a
more direct causative influence of HDL particles on fetal
growth cannot be ruled out given the emerging recognition of complex changes in HDL subclass structure and
function during pregnancy and their relationship with
birth outcomes.

Conclusions
In conclusion, the preliminary results of this pilot study
suggest that total particle concentrations of VLDL/CM
and HDL in mid-pregnancy have divergent associations
with birth weight, potentially reflecting the specific roles
of these lipoprotein particles with respect to placental
function and fetal growth. However, our findings must be
interpreted with caution given several limitations including a small sample size potentially reflecting a type-1 statistical error, lack of statistical power to examine effect
modification by infant sex, collection of birth outcome
data with a maternal-reported birth outcome questionnaire, restriction of our analyses to one mid-pregnancy
timepoint, and a lack of diversity with respect to race/
ethnicity and education. Despite these limitations, our
findings can inform future work to examine how the
trajectory of lipoprotein distribution across pregnancy
influences birth outcomes in a larger and more diverse
longitudinal cohort.
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